Friday, 28 Feb 2020

You are here

Hospitalized Infections are Higher with the Second Biologic

Using Medicare claims data on 189,326 RA patients, researchers at the University of Alabama at Birmingham examined the rates of hospitalized infections in previously biologic-treated RA patients and compared rates in cohorts starting new treatment with etanercept, adalimumab, certolizumab, golimumab, infliximab, abatacept, rituximab or tocilizumab. 

Among 31,801 new biologic starts, patients were treated with etanercept (12%), adalimumab (15.2%), certolizumab (5.9%), golimumab (4.4%), infliximab (12.4%), abatacept (28.9%), rituximab (14.8%), and tocilizumab (6.3%).  Concomitant steroids were used in 54-66% of patients and methotrexate use was highest with infliximab (61%) and lowest with certolizumab (53%). The comorbidity risk was similar across groups.

Overall, 2,530 hospitalized infections were identified during the follow-up period (2006-2011), with incidence rates varying from 13.1 for abatacept to 18.7 for rituximab per 100 person-years. Compared with abatacept, the adjusted hazard ratios were significantly higher for etanercept (HR 1.24), infliximab (1.39) and rituximab (1.36). Rates of hospitalized infections were similar (not increased) for those taking adalimumab, certolizumab, golimumab, and tocilizumab, compared to abatacept. Mortality rates (5%) were the same for all groups. 

RA patients who were previously treated with a biologic have an increased risk of hospitalized infections with the start of a new biologic, with a crude incidence rate of 15.3 (95% CI: 14.7-15.9) per 100 person-years. This number stands out against rates seen with biologic-naive patients.  The historic rate of serious infections in RA (3-9/100PY) in the pre-biologic era and the serious infection rates reported for each biologic in the product label (2-6/100PY) are lower than that reported in this cohort.  

While there was a 40% difference in relative risk between the agents reported herein, the absolute risk of hospitalized infection was modest; 5.6 per 100 person years at most.  Yun and coworkers have shown that RA patients previously exposed to biologics had a significantly higher one-year risk of hospitalized infection when exposed to etanercept, infliximab and rituximab compared to abatacept.

Disclosures: 
The author has received compensation as an advisor or consultant on this subject

Add new comment

More Like This

Overmedication of America

Recent research from the Lown Institute reports that 750 older Americans are hospitalized daily because of serious side effects from and the core problem is that of polypharmacy, especially in the elderly. 

Best of 2019 - Biologic Safety Guidelines from the British Society for Rheumatology

In the United Kingdom, NICE has looked to the British Society of Rheumatology (BSR) to develop evidence based guidance on the safe use of biologic DMARDs in patients with inflammatory arthritis. This guidance document on biologic safety covers baseline screening, monitoring, effect of co-morbidities, and when or under what circumstances biologic therapy should be interrupted.

Best of 2019 - Methotrexate and the Risk of Lung Disease

Rheumatology has a comprehensive overview of methotrexate (MTX) and the risk of lung injury, MTX-related pneumonitis and interstitial lung disease (RA-ILD) with rheumatoid arthritis (RA). Past reports suggest the frequence of MTX-pneumonitis to be between 0.3 and 11.6%; recent studies suggest it may be much lower.

No Cancer Risk with Systemic Necrotizing Vasculitis

The French Vasculitis Study Group has published that patients with systemic necrotizing vasculitis do not have an increased risk of malignancy; in fact they have a risk that is similar to the general population.

Previous reports have suggested either no risk or a declining risk in the era of better therapies for vasculitis. 

FDA Warns 15 CBD Manufacturers

Today, the U.S. Food and Drug Administration issued warning letters to 15 companies for illegally selling products containing cannabidiol (CBD) in ways that violate the Federal Food, Drug, and Cosmetic Act (FD&C Act).  This warning affirms that the FDA has not determined the many preparations of cannabidiol to be safe or effective.